Dark

CANF
Can-Fite BioPharma Ltd.
stock NYSEAMERICAN ADR

At Close

May 8, 2025 3:59:46 PM EDT

1.12USD+1.364%(+0.02)98,405

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 8, 2025 8:53:30 AM EDT

1.14USD+3.564%(+0.04)379

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 31, 2022

07:07AM EST Can Fite Says First Patient Enrolled In Phase IIb NASH Clinical Trial With Namodenoson RTTNews

07:06AM EST Can Fite Announces First Patient Enrolled In Phase IIb NASH Clinical Trial With Namodenoson Benzinga

Jan 21, 2022

11:40AM EST CanFite Shares Quiet Following US National Institutes Of Health ClinicalTrials.gov Listing For Co.'s 'Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis' Benzinga

Jan 14, 2022

04:48PM EST Can-Fite Files For Offering Of Up To 190.5M Shares Benzinga

Jan 13, 2022

11:47AM EST The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact Benzinga

11:45AM EST Can-Fite BioPharma Announces Pre-Clinical Studies Showing Piclidenoson 'Destroys Pathological Skin Cells in vitro' Benzinga

Jan 5, 2022

07:07AM EST Can-Fite BioPharma Expects Several Significant And Value-driving Events RTTNews

07:00AM EST Can-Fite Issues Letter to Shareholders Business Wire

Dec 29, 2021

07:04AM EST Can-Fite Announces Filing Patent Of Applications For Treatment Of Various Advanced Solid Tumors Benzinga

Dec 20, 2021

04:07PM EST Can-Fite Announces Exercise Of Warrants For Cash Proceeds Of $10M Benzinga

02:49PM EST Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher Benzinga

12:35PM EST Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump Benzinga

10:03AM EST Can-Fite BioPharma Ltd. (CANF) shares are soaring on Monday morning trade after the company announced that the last patient treated under phase II study of Namodenoson hepatocellular carcinoma or HCC experienced a complete response and cleared all cancer lesions. HCC is a common form of liver cancer. RTTNews

08:01AM EST Can-Fite BioPharma Ltd. (CANF) said the last patient treated under an Open Label Extension program of its concluded phase II study of Namodenoson in the treatment of hepatocellular carcinoma reported a Complete Response. The patient has now survived five years, and completed clearance of all cancer lesions. RTTNews

07:13AM EST Liver Cancer Patient Treated With Can-Fite's Namodenoson Clears All Cancer Lesions Under Phase II Study; Stock Up RTTNews

07:03AM EST Can-Fite BioPharma Announces Liver Cancer Patient Treated With Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study Benzinga

07:00AM EST Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study Business Wire

Dec 7, 2021

07:05AM EST Can-Fite Says Phase 3 Psoriasis Study To Complete 16-Week Treatment Of Last Patient In January; Sees Topline Data In Q1 RTTNews

07:03AM EST Can-Fite's Phase III Psoriasis Study To Complete 16-Week Treatment Of Last Patient In January; Topline Data Expected Q1 2022 Benzinga

Nov 26, 2021

08:22AM EST Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates Benzinga

07:25AM EST Can-Fite BioPharma Ltd. (CANF) on Friday reported net loss of $8.49 million for $0.02 per share for the 9-month period ended September 30, 2021, narrower than $11.53 million or $0.04 per share in the same period last year, primarily due to decrease in research and development expenses. RTTNews

07:06AM EST Can-Fite BioPharma 9-month Loss Per Share $0.02 Vs Loss $0.04 Last Year RTTNews

07:01AM EST Can-Fite Biopharma Nine Month EPS $(0.02) Benzinga

07:00AM EST Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update Business Wire

Nov 24, 2021

07:00AM EST Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021 Business Wire

Nov 23, 2021

07:18AM EST Can-Fite's Piclidenoson Commences Clinical Study For Treatment Of Canine Osteoarthritis Benzinga

Nov 12, 2021

07:00AM EST Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference Business Wire

Nov 1, 2021

07:03AM EDT Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting 2021 Conference Benzinga

Oct 28, 2021

07:51AM EDT Can-Fite's NASH Patents Granted And Allowed In Japan, Hong Kong, And Mexico Benzinga

Oct 26, 2021

07:10AM EDT Can-Fite CEO To Present Namodenoson's Clinical Trial Data As Expert Speaker At 5th Annual Antifibrotic Drug Development Summit Nov. 1-3 Benzinga

07:00AM EDT Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit Business Wire

Oct 21, 2021

12:12PM EDT Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal Benzinga

12:11PM EDT Can-Fite BioPharma Ltd Announces Positive Data From Phase IIa Can-Fite NASH Study Published In Leading Peer Reviewed Scientific Journal Benzinga

Oct 8, 2021

08:48AM EDT Hope on the Horizon for Liver Cancer Patients as This Company's Namodenoson Drug Starts Pivotal Phase III Global Trial Benzinga

Oct 5, 2021

07:00AM EDT Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 Business Wire

Sep 22, 2021

07:00AM EDT Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021 Business Wire

Sep 17, 2021

07:00AM EDT Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences Business Wire

Sep 9, 2021

07:00AM EDT Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire

Sep 2, 2021

07:10AM EDT Can-Fite BioPharma Completes Patient Enrollment In Phase III Psoriasis Study RTTNews

07:04AM EDT Can-Fite Reports Completion Of Patient Enrollment In Phase 3 Psoriasis Study; Topline Results Expected In Q1'22 Benzinga

07:00AM EDT Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study Business Wire

Aug 26, 2021

04:34PM EDT Can-Fite BioPharma F-1 Shows Registration For 5.35M ADS Offering Via Selling Shareholders Benzinga

12:48PM EDT Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY Benzinga

07:25AM EDT Can-Fite H1 Net Loss $5.09 Mln Vs Loss $8.23 Mln Last Year RTTNews

07:14AM EDT Can-Fite Reports First Half EPS $(0.01) Up From $(0.04) YoY, Sales $398K Down From $402K YoY Benzinga

07:00AM EDT Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update Business Wire

Aug 12, 2021

08:02AM EDT Can-Fite BioPharma Reports 5M Share Offering Priced At $2/ADS Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

07:01AM EDT Can-Fite Says Has Completed Preparatory Work Ahead Of Initiation Of Enrollment For Phase III Liver Cancer Study Benzinga

07:00AM EDT Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study Business Wire

Jun 28, 2021

09:11AM EDT Can-Fite Stock Gains On Piclidenoson Development Pact For Pets Benzinga

07:19AM EDT Can-Fite BioPharma Ltd. (CANF) said it has reached a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. RTTNews

07:15AM EDT Can-Fite BioPharma Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets Benzinga

07:00AM EDT Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets Business Wire

Jun 24, 2021

10:11AM EDT Aegis Capital Initiates Coverage On Can Fite Biofarma with Buy Rating, Announces Price Target of $5 Benzinga

Jun 16, 2021

07:45AM EDT Can-Fite Receives Notice Of Patent Allowance In China For NASH Treatment Benzinga

Jun 3, 2021

11:06AM EDT CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS Benzinga

Jun 2, 2021

07:37AM EDT Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson Benzinga

07:00AM EDT Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021 Business Wire

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

07:14AM EDT Can-Fite Reports Q1 Breakeven Per Share Vs Loss $0.03 Last Year RTTNews

07:03AM EDT Can-Fite Biopharma Q1 EPS $0.00 Up From $(0.03) YoY, Sales $148.00K Down From $198.00K YoY Benzinga

07:00AM EDT Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update Business Wire

06:00AM EDT Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report(r) Business Wire

May 13, 2021

11:25AM EDT From BZ Small Cap Event: Can-Fite CEO Says Co. Looking To Partner for Its Molecule Expected To Be Used As Erectile Dysfunction Candidate Benzinga

11:24AM EDT From BZ Small Cap Event: Can-Fite CEO Sees Phase 2a Study Initiation For Its NASH Drug Candidate In Q4'21 Benzinga

11:23AM EDT From BZ Small Cap Event: Can-Fite CEO Sees Phase 3 Study Initiation For Its Live Cancer Drug Candidate In Q4'21 Benzinga

11:21AM EDT From BZ Small Cap Event: Can-Fite CEO Highlights Typical Deal Structure That Encompasses Its Business Development Strategy: Upfront Payments For Distribution, Regulatory Milestone Payments, Royalties And Sales Milestone Payments Benzinga

11:18AM EDT From BZ Small Cap Event: Can-Fite CEO Highlights Co.'s Drug Development Pipeline: Piclidenoson For Psoriasis, COVID-19, Namodenoson For Liver Cancer, NASH, CF602 For Erectile Dysfunction and Ongoing Pre-Clinical Trials For Cannabinoids Benzinga

11:14AM EDT Can-Fite CEO Pnina Fishman Begins Presentation At BZ Small Cap Event Benzinga

08:26AM EDT Benzinga Pro's Top 6 Stocks To Watch For Thursday, May 13, 2021 (BZ Small Cap Event Edition): UGRO, CANF, MYMD, OBLG, ELYS, GNPX Benzinga

May 12, 2021

09:30AM EDT CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATES Benzinga

May 6, 2021

07:00AM EDT Can-Fite to Present at Benzinga's Global Small Cap Conference on May 13, 2021 Business Wire

Apr 29, 2021

09:02AM EDT Can-Fite's Phase III Psoriasis Study Achieves 75% Enrollment RTTNews

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

07:10AM EDT Can-Fite Reports Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Benzinga

07:00AM EDT Can-Fite's Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Business Wire

Apr 22, 2021

08:07AM EDT Can-Fite Expands Mid-Stage COVID-19 Study To Europe Benzinga

07:22AM EDT Can-Fite Expands Its Phase II COVID-19 Study To Romania And Bulgaria Benzinga

Apr 20, 2021

11:18AM EDT Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing Benzinga

08:06AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Apr. 20, 2021: IBM, PLAY, SNDX, NKE, CANF Benzinga

07:05AM EDT Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates Benzinga

Apr 5, 2021

01:55PM EDT Can-Fite shares were trading higher after the company announced positive results from a pre-clinical study of CBD and liver cancer cell growth. Benzinga

11:46AM EDT Can-Fite Says Cannabinoid-Based Therapies Stop Liver Cancer Growth, Preclinical Studies Show Benzinga

07:03AM EDT Can-Fite BioPharma Announces Completion of a Pre-Clinical Study Demonstrating that a CBD Tich T3/C15 Cannabis Fractioninduces Inhibition of Liver Cancer Cell Growth Benzinga

07:00AM EDT Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies Business Wire

Mar 25, 2021

09:00AM EDT Can-Fite BioPharma Ltd. (CANF) reported that its net loss for the year ended December 31, 2020 widened to $14.44 million from last year's $12.62 million, due to a decrease in revenues in 2020 and an increase in research and development expenses which were partly offset by a decrease in finance expenses, net. RTTNews

08:40AM EDT Can-Fite BioPharma 2020 Net Loss Widens To $14.44 Mln From $12.62 Mln Prior Year RTTNews

08:31AM EDT Can-Fite FY20 Sales $760K, Down From $2.03M YoY Benzinga

08:29AM EDT Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update Business Wire

Mar 23, 2021

11:47AM EDT The Market Slows Down As Q1 Closes Out Benzinga

Mar 19, 2021

07:00AM EDT Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report(r) Business Wire

Mar 18, 2021

07:19AM EDT Can-Fite Announces New Data Showing Topical Administration Of CF602 Resulted Statistically Significant Improvement In Erectile Dysfunction In Diabetic Model Benzinga

Mar 16, 2021

02:46PM EDT Mid-Afternoon Market Update: Crude Oil Down 1%; SunLink Health Systems Shares Spike Higher Benzinga

02:46PM EDT Mid-Day Market Update: Dow Falls 100 Points; Can-Fite BioPharma Shares Jump Benzinga

10:36AM EDT Mid-Morning Market Update: Markets Mixed; Jabil Beats Q2 Views Benzinga

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

07:04AM EDT Can-Fite BioPharma Signs $42.7 Mln Out-Licensing Deal With Ewopharma RTTNews

07:02AM EDT Can-Fite Signs $42.7M Out-Licensing Deal With Ewopharma; Ewopharma To Pay Can-Fite $2.25M Upfront And Additional $40.45M Upon Achievement Of Milestones Benzinga

07:00AM EDT Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma Business Wire

Mar 5, 2021

07:08AM EST Can-Fite Enrolls First Of 40 Patients In Phase II COVID-19 Study Under FDA Protocol RTTNews

07:04AM EST Can-Fite Enrolls First Patient In Phase II Piclidenoson Study FOR COVID-19 Benzinga

07:04AM EST Can-Fite Reports Enrollment Of First Patient In Phase 2 COVID-19 Study Under FDA Protocol Benzinga

07:00AM EST Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol Business Wire

Feb 22, 2021

08:21AM EST Can-Fite BioPharma's Namodenoson Improves Liver Function, Long Term Data Shows Benzinga

07:15AM EST Can-Fite Biopharma Highlights New Data From Phase II Liver Cancer Study, Including Overall Survival Of ~4 Years In Two Patients Treated With Namodenoson; Says 'Namodenoson continues to demonstrate a good safety profile and is well tolerated' Benzinga

07:10AM EST New Positive Data from Can-Fite's Liver Cancer Phase II Clinical Study with Namodenoson Business Wire

Feb 16, 2021

12:46PM EST 43 Stocks Moving In Tuesday's Mid-Day Session Benzinga

Feb 1, 2021

07:25AM EST Can-Fite BioPharma Announces Inhibition Of Liver Fibrosis By Cannabis Compounds In Preclinical Studies RTTNews

07:12AM EST Can-Fite Completes Set Of Preclinical Studies Demonstrating That 'CBD rich T3/C15 cannabis fraction induces an inhibitory effect on liver fibrosis' Benzinga

07:00AM EST Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies Business Wire

Jan 28, 2021

07:01AM EST Can-Fite's NASH Indication Highlighted in Webinar by KOL Dr. Harrison: "Namodenoson May Have Big Impact on NASH" Business Wire

Jan 19, 2021

01:26PM EST Piclidenoson From Can-Fite Biopharma Shows New, Promising Developments For Psoriasis Treatment Benzinga

Jan 8, 2021

07:14AM EST Can-Fite Says Namodenoson Liver Cancer Study Published In Peer Reviewed Journal-Cancers RTTNews

07:01AM EST Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed JournalCancers Benzinga

Dec 15, 2020

07:07AM EST Can-Fite Receives Israel Ministry Of Health Approval To Conduct Research With Cannabinoids In Cancer, Inflammation And Obesity At Company Discovery Labs Benzinga

Dec 14, 2020

07:05AM EST Can-Fite Says Currently Engaged In Design Of Phase IIb Study For Namodenoson In Treatment Of NASH RTTNews

07:00AM EST Can-Fite Reports on Progress With Its Namodenoson NASH Program Business Wire

Dec 5, 2020

04:53PM EST The Week In Cannabis: MORE Act Passes, UN Vote, Joe Rogan, Will.i.am, Aphria, Canopy And Earnings Benzinga

Dec 3, 2020

07:00AM EST Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020 Business Wire

Nov 30, 2020

07:11AM EST Can-Fite BioPharma 9-month Net Loss $10.81 Mln Vs. Net Loss $7.84 Mln Last Year RTTNews

07:07AM EST Can-Fite Reports EPS Of $(0.03) For Nine Months Ended Sept. 30 Benzinga

07:00AM EST Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update Business Wire

04:11AM EST Earnings Scheduled For November 30, 2020 Benzinga

Nov 24, 2020

07:00AM EST Can-Fite's Namodenoson Abstract Selected as 'Best of The Liver Meeting' in the NASH Category of the American Association of Liver Diseases (AASLD) Business Wire

Nov 23, 2020

07:00AM EST Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET Business Wire

Nov 16, 2020

07:14AM EST Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases Conference Benzinga

07:00AM EST Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference Business Wire

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 9, 2020

07:00AM EST Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 Business Wire

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 13, 2020

07:00AM EDT Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 Business Wire

Oct 6, 2020

07:43AM EDT Can-Fite Announces Independent Data Monitoring Committee Recommended Co. Continue With Phase III Psoriasis Study, Recommended Not To Continue With Rheumatoid Arthritis Study Benzinga

07:34AM EDT Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis RTTNews

Sep 30, 2020

07:14AM EDT Can-Fite To Present Namodenoson Phase II Results At American Association For The Study Of Liver Diseases Conference Nov. 13-16 Benzinga

07:00AM EDT Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson's Treatment of NASH at American Association for the Study of Liver Diseases Conference Business Wire

Sep 22, 2020

07:00AM EDT Can-Fite to Participate in Two BioPharma Partnering Conferences Business Wire

Sep 8, 2020

07:00AM EDT Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 Business Wire

Aug 31, 2020

07:02AM EDT FDA Issues 'Safe to proceed' Notice For Can-Fite's Investigational New Drug Application For Phase II Study Of Piclidenoson In COVID-19 Benzinga

07:00AM EDT FDA Clears Can-Fite to Commence Phase II COVID-19 Study Business Wire

Aug 27, 2020

07:05AM EDT Can-Fite 5-month Loss Per Share $0.04 Vs Loss $0.08 Last Year RTTNews

07:00AM EDT Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update Business Wire

04:03AM EDT Earnings Scheduled For August 27, 2020 Benzinga

Aug 25, 2020

08:15AM EDT Can-Fite Receives Notification Of Patent Grant From European Patent Office For Namodenoson In The Treatment Of NASH Benzinga

Aug 20, 2020

07:00AM EDT Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET Business Wire

Jul 27, 2020

07:14AM EDT Can-Fite Submits IND To FDA For COVID-19 Phase II Study Of Piclidenoson RTTNews

07:03AM EDT Can-Fite Submits Investigational New Drug Application To FDA For COVID-19 Phase II Study Benzinga

07:00AM EDT Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study Business Wire

Jul 20, 2020

07:10AM EDT Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds Benzinga

Jul 15, 2020

07:32AM EDT Shares of Can-Fite BioPharma Ltd. (CANF) are rising over 33% in pre-market today, after the company announced that it has amended the protocol for its Phase II COVID-19 study based on the U.S. FDA feedback. RTTNews

07:19AM EDT Can-Fite BioPharma Ltd. (CANF) announced that it has amended its Phase II COVID-19 study protocol based on inputs from the U.S. Food and Drug Administration or FDA and its Pre-Investigational New Drug or IND fling. RTTNews

07:08AM EDT Can-Fite BioPharma Amends Phase II COVID-19 Study Protocol Based On Inputs From FDA RTTNews

07:02AM EDT Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Says Plans to File IND Shortly Benzinga

07:00AM EDT Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly Business Wire